Amiparty Bag Injection 5%

Adult dosage

Adult: Intravenous infusion at a total amino acid dose of 1.5 g per kg of body weight per day, with a maximum dosage corresponding to 2100 mL per day for a weight of 70 kg. Administration rate: Infuse 1.7-2.1 mL per kg of body weight over 60 minutes (for a weight of 70 kg, about 40-50 drops per minute).

This medicine must be used according to a doctor's instructions and should not be taken based on personal judgment. It should not be used in patients with severe kidney dysfunction or high nitrogen levels in the blood, patients with abnormalities in amino acid metabolism, and metabolic disorders with issues using nitrogen. It should also not be administered to patients with very weak cardiac function such as wasting heart failure or those with pulmonary edema, or to patients with very low or no urine output. Caution is needed in patients with hypernatremia, hyperchloremia, or alkalosis if sodium or chloride ions are present; with magnesium ions, it should not be given to patients with AV block or severe myasthenia gravis. This medicine should not be used in patients who have been overloaded with fluid or have a history of myocardial infarction. In patients with severe acidosis, congestive heart failure, severe heart failure, edema due to sodium retention, hyperkalemia or potassium retention, and decreased kidney function, it should be administered carefully. When taking this medicine, rare allergic reactions such as skin rash may occur, and if such symptoms appear, administration must be stopped immediately. Occasionally, gastrointestinal symptoms such as nausea or vomiting can occur, and cardiovascular symptoms such as chest discomfort, rapid heart rate, and increased blood pressure may also be experienced. Administering large volumes quickly can result in acidosis, so caution is necessary. Severe side effects such as chills, fever, headache, respiratory distress, respiratory arrest, shock, bronchospasm, and urinary tract spasm can occur rarely. If magnesium ions are present, peripheral blood vessels may dilate, leading to lowered blood pressure. Metabolic complications such as metabolic acidosis, hypophosphatemia, alkalosis, increased blood sugar, diabetes, dehydration, rebound hypoglycemia, elevated liver enzymes, vitamin deficiencies or excesses, electrolyte imbalances, and pediatric hyperammonemia may occur. In patients with decreased liver or kidney function, serum BUN levels may rise, and severely liver-impaired patients may experience amino acid imbalances in the blood, metabolic alkalosis, systemic nitrogen blood syndrome, hyperammonemia, altered consciousness, and coma. During treatment, serum ammonia levels may fluctuate, so regular monitoring is essential. Excessive administration can lead to electrolyte imbalances, so electrolyte status should be closely monitored, especially when using electrolyte-containing solutions together. Overdosing may result in metabolic alkalosis; therefore, solutions containing acetate ions should be used cautiously. In patients with kidney disease, pulmonary disease, or severe heart disease, care should be taken to avoid excessive fluid retention during administration. In diabetic patients, it is safe to frequently monitor blood sugar levels during administration. Patients with hyponatremia, impaired liver function, or impaired kidney function should have their doses adjusted individually, and fluid balance and serum electrolyte levels should be meticulously managed. There are also interactions with other drugs, particularly tetracycline antibiotics, as using them alongside this medicine may reduce its protein-sparing effect. If magnesium ions are present, caution is needed as intravenous administration of calcium salts can precipitate magnesium salts. For pregnant women, the safety of this medication has not been sufficiently established; it should only be given when the benefits of treatment outweigh the risks. When administering to children, liver function may be immature, so it is advisable to maintain a low concentration, especially since infants may lack the capacity for urea synthesis, which can lead to hyperammonemia; thus, serum ammonia levels should be monitored frequently. Elderly patients may have diminished physical function, so it is necessary to administer at a slow rate and reduce the dosage accordingly. This medication contains electrolytes, so when administered in large amounts or in combination with electrolyte solutions, special care must be taken to maintain electrolyte balance, and it must be administered slowly intravenously. Rapid infusion may cause chills or vomiting, and a significant amount of amino acids may be excreted through the kidneys. In winter or cold environments, it is advisable to warm the medication to body temperature before use. During the administration process, there is a risk of infection, so thorough sterilization of the solution preparation and injection devices is necessary, and cloudy or discolored solutions should not be used. The solution should be used promptly after mixing and is safe to use within 24 hours if stored in the refrigerator. If crystals form in the solution, it should be heated to about 50-60 degrees and then cooled to body temperature for use. When storing, soft bag products do not require venting, while vial products must be vented just before use to prevent leakage. The actual dose should be taken with respect to the container markings.

Serious side effects

• Respiratory distress
• respiratory arrest
• shock
• bronchospasm
• increased blood pressure
• kidney failure
• liver failure
• coma

Mild side effects

• Rash
• nausea
• vomiting
• chest discomfort
• palpitations
• tachycardia
• increased blood pressure
• chills
• fever
• headache

This medicine should be stored in a sealed container to protect it from air and moisture. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius. Proper storage ensures the efficacy of the medication is well maintained and allows for safe use.

Appearance

A colorless to pale yellow transparent injection in a plastic container for infusion.

Package unit

250 milliliters/box, 100 milliliters/box